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creativecommons.org/licenses/by-nc-nd/Abstract Background: Cabozantinib is an inhibitor of tyrosine kinases, including
MET, vascular endothelial growth factor receptor, AXL and RET. This multi-cohort phase
II randomised discontinuation trial explored anticancer activity of cabozantinib in nine
tumour types.
Patients and methods: Cabozantinib was administered (100 mg, once daily) to patients with
advanced, recurrent or metastatic cancers. Those with stable disease at week 12 were rando-
mised 1:1 to cabozantinib or placebo. Primary end-points were objective response rate
(ORR) at week 12 and progression-free survival (PFS) in the randomised phase.
Results: A total of 526 patients were enrolled. The highest ORR was observed in ovarian
cancer (OC) (21.7%); the largest PFS benefit was observed in castration-resistant prostate
cancer (CRPC) (median 5.5 versus 1.4 months for placebo; hazard ratio 0.14, 95% confidence
interval: 0.04, 0.52). Disease control rates were >40% for CRPC, OC, melanoma, metastatic
breast cancer (MBC), hepatocellular carcinoma (HCC) and nonesmall cell lung cancer. Me-
dian duration of response ranged from 3.3 (MBC) to 11.2 months (OC). Encouraging efficacyf General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Faculty of Medicine,
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P. Scho¨ffski et al. / European Journal of Cancer 86 (2017) 296e304 297results and symptomatic improvements prompted early suspension of the randomised stage
and conversion to open-label non-randomised expansion cohorts. Dose reductions to
manage adverse events (AEs) occurred in 48.7% of patients. The most frequent grade III
eIV AEs were fatigue (12.4%), diarrhoea (10.5%), hypertension (10.5%) and palmar-
plantar erythrodysesthesia syndrome (8.7%).
Conclusions: Clinical antitumour activity of cabozantinib was observed in a subset of tumour
types: CRPC and OC were evaluated further in expansion cohorts. Phase III programs were
initiated in CRPC and HCC. Interpretation of efficacy outcomes was limited by early termi-
nation of the randomised portion of the trial.
Trial registration number: NCT00940225.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cabozantinib, a small-molecule tyrosine kinase inhibitor
(TKI), inhibits multiple receptor tyrosine kinases that
are important in cancer pathobiology, including MET,
the three vascular endothelial growth factor receptors
(VEGFRs), AXL and RET. In preclinical studies,
cabozantinib treatment was shown to inhibit tumour
angiogenesis, invasiveness, metastasis and tumour pro-
gression [1e3]. In xenograft models, the primary effect
of cabozantinib was the inhibition of tumour growth
rather than volumetric shrinkage, suggesting that the
primary clinical benefit of cabozantinib may be disease
stabilisation. Therefore, classical oncology paradigms
for phase II clinical evaluation (e.g. single-arm, non-
controlled studies using objective response rate [ORR]
as the primary end-point) might not adequately
demonstrate the antitumour activity of cabozantinib.
Tumour stabilisation is best measured through the
use of a controlled study, which ensures that differences
detected between experimental and control arms are due
to cytostatic activity and not the inherent indolent na-
ture of a tumour [4,5]. In settings without an appro-
priate active control, a randomised discontinuation trial
(RDT) attempts to assess cytostatic effect while limiting
placebo exposure [6e8]. In RDTs, patients achieving
tumour stabilisation while receiving experimental treat-
ment during an initial lead-in period are identified as
potentially experiencing cytostatic benefit. At a pre-
defined time point, these patients are randomised to
either continue experimental treatment or to receive
placebo. Through this process, heterogeneity to drug
response is decreased within the randomised population
compared with studies carrying out randomisation at
initiation.
The objective of the present multi-cohort phase II
RDT was to evaluate the clinical anticancer activity of
cabozantinib for multiple solid-tumour types. The trial
used an adaptive design, whereby a study oversight
committee reviewed ongoing efficacy and safety data
and made recommendations for cohort enrolment and
study conduct.2. Patients and methods
2.1. Patients
This phase II RDT evaluated the antitumour activity of
cabozantinib in nine solid-tumour types, which defined
individual cohorts (ClinialTrials.gov, NCT00940225).
The RDT design consisted of a 12-week lead-in stage
with open-label treatment of cabozantinib followed by
a placebo-controlled randomised stage for patients
who achieved stable disease (SD) during the lead-in
stage (Fig. 1). The study protocol was approved by all
local/institutional review boards for human
investigations as appropriate, and all patients provided
written informed consent. Eligible patients had
pathologically confirmed malignant solid tumours in
an advanced, recurrent or metastatic stage with
measurable disease by Response Evaluation Criteria in
Solid Tumours (RECIST) version 1.0 [9]. Patients were
enrolled in the following tumour cohorts: castration-
resistant prostate cancer (CRPC), melanoma (MEL),
ovarian cancer (OC; epithelial ovarian cancer, primary
peritoneal or fallopian tube carcinoma), nonesmall
cell lung cancer (NSCLC), metastatic breast cancer
(MBC), hepatocellular carcinoma (HCC), gastric/
gastroesophageal junction adenocarcinoma (GC),
small-cell lung cancer (SCLC) and pancreatic
adenocarcinoma (PAC). Additional eligibility criteria
for the tumour cohorts are included in the
Supplementary Information-Tumour-specific cohort
eligibility.
2.2. Study drug administration
During the 12-week lead-in stage, patients received 100-
mg daily doses of cabozantinib capsules. After this lead-
in stage, study sites randomised patients via an inter-
active web response system, which provided a blinded
study drug package identifier. Cabozantinib and placebo
were colour-, size- and shape-matched; patients and
study site personnel were blinded to treatment assign-
ment. The randomisation schedule was stratified by
Fig. 1. Multi-cohort randomised discontinuation trial design. CR, complete response; CRPC, castration-resistant prostate cancer; GC,
gastric/gastroesophageal junction adenocarcinoma; HCC, hepatocellular carcinoma; MBC, metastatic breast cancer; MEL, melanoma;
NSCLC, nonesmall cell lung cancer; OC, ovarian cancer; PAC, pancreatic adenocarcinoma; PD, progressive disease; PR, partial
response; SCLC, small-cell lung cancer; SD, stable disease.
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blocks were used to maintain the 1:1 ratio between
cabozantinib and placebo arms.
Protocol-defined dose modifications, including inter-
ruptions (up to 3 weeks) and dose reductions, were used
to manage adverse events (AEs). Treatment could be
reduced at the discretion of the investigator to 60 mg,
40 mg and then 20 mg. Patients could continue treat-
ment until disease progression or unacceptable toxicity.
Study treatment in the randomised stage was adminis-
tered in a double-blind fashion.
2.3. Study assessments
The primary end-point of the lead-in phase was ORR at
week 12, and the primary end-point of the randomised
phase was PFS. Additional end-points included the
disease control rate (DCR) at week 12, duration of
response (DOR) and PFS from first dose of cabozanti-
nib in all patients. Tumour assessments by computed
tomography or magnetic resonance imaging were per-
formed at screening and every 6 weeks after the first
dose of study treatment. Tumour response and pro-
gression were determined by the investigator using
RECIST 1.0. Imaging continued until permanent
discontinuation of study treatment due to documented
progressive disease (PD) or initiation of subsequent
anticancer therapy. Changes in tumour markers were
not considered for determination of progression.
Although study treatment could be discontinued upon
clinical deterioration, every effort was made to docu-
ment radiographic progression.
Safety was evaluated by assessment of AEs, vital
signs, electrocardiograms and standard laboratory tests.
Seriousness of AEs, severity grade per Common Ter-
minology Criteria for Adverse Events, version 3.0, and
relationship to study treatment were assessed by the
investigator.2.4. Statistical considerations
The study used an adaptive design with an assumed SD
rate of 35% at week 12 to estimate the target enrolment
from the number of patients planned for randomisation
(Supplementary Fig. S1). The target enrolment of 200
patients per cohort was chosen to achieve the goal of 70
randomised patients and 52 events post randomisation.
The design had an 80% power to detect a hazard ratio
(HR) of 0.5 for progression-free survival (PFS) between
cabozantinib and placebo with a two-sided alpha of 0.1.
Under this design, the minimum observed effect that
would demonstrate statistical significance for PFS was a
58.7% improvement (HRZ 0.63). Given that this was a
phase II trial intended to generate hypotheses for further
study, there was no adjustment for multiple compari-
sons. Up to an additional 300 patients could be enrolled
in cohorts deemed not suitable for full accrual to the
randomised stage. The study oversight committee was
responsible for prioritisation of tumour cohorts based
on continuous review of emerging efficacy and safety
data. Stopping rules were based on conditional proba-
bility to project futility (e.g. enrolment was suspended in
tumour cohorts deemed unlikely to benefit from cabo-
zantinib or if the ORR after the 12-week lead-in stage
was higher than anticipated such that the randomised
stage was unwarranted).
ORR was defined as the proportion of patients with a
best overall response of confirmed complete response
(CR) or partial response (PR) during the lead-in stage.
PFS in the randomised stage was defined as the time
from randomisation until the earlier of radiographic
progression or death. The comparison of PFS between
the cabozantinib and placebo arms was performed using
the log-rank test in the randomised population. The
median duration of PFS and the associated 95% confi-
dence interval (CI) for each treatment arm were esti-
mated using the KaplaneMeier method. The HR was
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as the only covariate.
DOR was summarised for patients treated in the
lead-in and/or randomised stage and was defined as the
time from the tumour assessment of the first docu-
mented PR or CR that was subsequently confirmed at
least 28 d later until the date of disease progression.
Median DOR and the associated 95% CI were esti-
mated using the KaplaneMeier method. DCR was
defined as the proportion of patients treated in the
lead-in stage with a best overall response of CR, PR or
SD at Week 12.
PFS from first dose of cabozantinib in all patients
was estimated using a piecewise method. For this ana-
lysis, all patients contributed to the PFS estimate for the
first 12 weeks of therapy. PFS after week 12 was esti-
mated using a weighted average of group-specific PFS
from the two groups continuously treated with cabo-
zantinib: 1) continued open label and 2) randomised to
cabozantinib. When combining the group-specific PFS
estimates, the weights were the proportion of the sample
size of patients in the group of continued open label
versus patients in the randomised population [6].3. Results
3.1. Patients and treatment
Between September 2, 2009 and July 19, 2011, 795
patients were screened for eligibility, and 526 patients
were enrolled in nine tumour-specific cohorts at 42 sites
in the United States, Belgium, Israel and Taiwan.
Baseline characteristics and cohort distribution are
summarised in Supplementary Table S1, and a break-
down of metastatic areas can be found in
Supplementary Table S2. Among 526 patients who
received 1 dose of study treatment, 233 (44.3%) dis-
continued before completing the 12-week lead-in stage,
135 (25.7%) underwent randomisation at the end of
week 12 and 158 (30.0%) continued cabozantinib in the
open-label extension without being randomised, either
because they experienced PR or CR during the lead-in
stage or because randomisation was discontinued
before they reached week 12. Among 135 randomised
patients, 67 were randomly assigned to receive cabo-
zantinib and 68 to placebo. Of patients randomised to
placebo, 53 crossed over to receive open-label cabo-
zantinib, either after progression on placebo or when
the study was unblinded, and 15 discontinued without
crossing over (Supplementary Fig. S2). Median dura-
tion of exposure to cabozantinib was 86 d (range:
4e1232 d), and median average daily dose was 69.8 mg
(range: 15.4e100 mg). The most common reasons for
treatment discontinuation in the study were radio-
graphic progression (54.4%), AEs (20.3%) and clinical
deterioration (10.1%).3.2. Tumour response during the lead-in stage per
investigator
An ORR 10% was observed in three tumour cohorts:
OC, 21.7% (15/70); MBC, 13.6% (6/45) and NSCLC,
10% (6/60) (Table 1). One confirmed CR was observed
in the OC cohort. A reduction in the sum of target lesion
size was observed in 301 of 526 (57.2%) patients across
all tumour types (Fig. 2). DCRs at week 12  40% were
observed for HCC, CRPC, OC, MBC, SCLC and MEL.
Low rates (15%) of PD as best response were observed
in HCC, CRPC and OC.
3.3. Progression-free survival
Assessment of PFS during the randomised stage indi-
cated improvements in disease control with cabozanti-
nib compared with placebo in CRPC (median PFS, 5.5
versus 1.4 months; HR Z 0.14, 95% CI: 0.04, 0.52),
MEL (4.5 versus 2.8 months; HRZ 0.47, 95% CI: 0.16,
1.35) and HCC (2.5 versus 1.4 months; HRZ 0.82, 95%
CI: 0.31, 0.12) (Table 1, Supplementary Fig. S3).
Characterisation of PFS during the randomisation stage
for the other tumour cohorts was not possible, given the
low number of events.
In the evaluation of PFS from the first dose of
cabozantinib in all patients, the highest median PFS
results were observed in the CRPC (6.8 months), OC
(5.5 months), HCC (5.2 months), MBC (4.3
months) and NSCLC (4.0 months) cohorts.
3.4. Safety
AEs, irrespective of causality, occurred in 99.6% of pa-
tients with 392 (74.5%) experiencing at least one grade
III AE (Table 2). The most common grade III AEs
were fatigue, 65 (12.4%); diarrhoea, 55 (10.5%); hyper-
tension, 55 (10.5%) and palmar-plantar eryth-
rodysesthesia syndrome, 46 (8.7%). Overall, 390 patients
(74.1%) had AEs leading to dose reduction or inter-
ruption. Dose reductions across all tumour cohorts
occurred in 256 (48.7%) patients, with 85 (16.2%) having
two dose reductions and 20 (3.8%) having three dose
reductions. Median time to first dose reduction was 47.5
d (range, 11e470). Deaths occurring through 30 d after
the last dose of cabozantinib were mainly related to
disease progression. Eleven patients (2.1%) continuously
treated with cabozantinib expired because of causes
other than disease progression (1 patient each died of
acute peritonitis, bilateral pneumonia, enterocutaneous
fistula, gastrointestinal bleeding, haemorrhage, perfo-
rated bowel, pneumonia, possible respiratory compro-
mise, respiratory insufficiency, septic shock and
unexplained death). One patient who crossed over from
placebo to cabozantinib had an unknown cause of
death, and one patient died of intracerebral haemor-
rhage while receiving treatment with placebo.
Table 1
Overview of efficacy results.
CRPCa MELa OCa,b NSCLCa MBCa,b HCCa GC SCLC PAC
(N Z 171) (N Z 77) (N Z 70) (N Z 60) (N Z 45) (N Z 41) (N Z 21) (N Z 21) (N Z 20)
Lead-in stage
Best overall response, n (%)
Confirmed CR 0 0 1 (1.4) 0 0 0 0 0 0
Confirmed PR 8 (4.7) 4 (5.2) 14 (20.3) 6 (10.0) 6 (13.6) 2 (4.9) 1 (4.8) 1 (4.8) 0
SD 129 (75.4) 43 (55.8) 35 (50.7) 29 (48.3) 25 (56.8) 31 (75.6) 8 (38.0) 12 (57.1) 11 (55.0)
PD 19 (11.1) 19 (24.7) 9 (13.0) 12 (20.0) 9 (20.5) 3 (7.3) 10 (47.6) 7 (33.3) 5 (25.0)
Unable to evaluate 1 (0.6) 0 3 (4.3) 1 (1.7) 0 1 (2.4) 0 0 0
Missing 14 (8.2) 11 (14.3) 7 (10.1) 12 (20.0) 4 (9.1) 4 (9.8) 2 (9.5) 1 (4.8) 4 (20.0)
ORR (CR þ PR), n (%) 8 (4.7) 4 (5.2) 15 (21.7) 6 (10.0) 6 (13.6) 2 (4.9) 1 (4.8) 1 (4.8) 0
95% CI 2.0, 8.7 1.8, 12.4 13.1, 32.4 4.4, 20.3 6.0, 25.7 0.9, 16.1 0.2, 21.8 0.2, 21.8 0%, 15.4
DCR (ORR þ SD), n (%)c 112 (65.5) 33 (42.9) 35 (50.0) 23 (38.3) 21 (46.7) 27 (65.9) 7 (33.3) 9 (42.9) 7 (35.0)
95% CI 58.0, 72.3 32.0, 54.7 38.5, 61.5 26.1, 51.8 31.7, 61.6 50.0, 79.5 14.6, 55.1 21.8, 66.0 15.4, 58.9
Randomised stage
Patients (cabo, pbo), n 31 (14, 17) 26 (13, 13) 13 (7, 6) 16 (8, 8) 10 (5, 5) 22 (10, 12) 5 (3, 2) 6 (4, 2) 6 (3, 3)
PFS cabo event count 9 7 5 4 3 9 1 3 2
Median PFS (95% CI), mo 5.5 (4.0, 8.5) 4.5 (1.8, 15.4) 4.9 (3.9, 13.6) 2.4 (1.4, 2.9) 6.9 (5.1, 13.5) 2.5 (1.3, 6.8) UE (2.3, UE) 5.5 (1.9, 6.9) 2.8 (1.5, 2.8)
PFS pbo event count 11 11 4 6 5 9 2 2 1
Median PFS (95% CI), mo 1.4 (1.3, 2.7) 2.8 (1.5, 5.5) 1.4 (1.3, UE) 2.4 (1.4, 2.66) 1.1 (0.2, 1.4) 1.4 (1.3, 4.2) 1.0 (0.7, 1.34) 1.5 (0.9, 2.2) 0.7 (UE, UE)
HR (95% CI) 0.14 (0.04, 0.52) 0.47 (0.16, 1.35) UE 0.94 (0.25, 3.54) UE 0.82 (0.31, 2.12) UE 0.24 (0.02, 2.67) UE
Log-rank test P value 0.001 0.15 0.004 0.93 0.002 0.66 0.09 0.21 0.08
Overall study
DOR, cabo patients, n 15 6 15 6 6 3 NAd NAd NAd
Median DOR (95% CI), mo 5.6 (4.3, 8.3) 5.6 (3.0, 13.9) 11.2 (7.2, UE) 6.9 (5.3, 10.7) 3.3 (2.8, 4.2) 4.2 (3.0, UE) NAd NAd NAd
PFS from start of study,
cabo patients, n
171 77 70 60 45 41 21 21 20
Median PFSe, mo 6.8 2.8 5.5 4.0 5.2 4.3 1.4 3.4 2.7
CI, confidence interval; cabo, cabozantinib; CR, complete response; CRPC, castration-resistant prostate cancer; DCR, disease control rate; DOR, duration of objective response; GC, gastric/
gastroesophageal junction adenocarcinoma; HCC, hepatocellular carcinoma; HR, hazard ratio; MBC, metastatic breast cancer; MEL, melanoma; NA, not applicable; NSCLC, nonesmall cell lung
cancer; OC, ovarian cancer; ORR, objective response rate; PAC, pancreatic adenocarcinoma; pbo, placebo; PD, progressive disease; PFS, progression-free survival; PR, partial response; SCLC, small-
cell lung cancer; SD, stable disease; UE, un-evaluable.
Best overall response was the proportion of patients treated in the lead-in stage with CR or PR through the week 12 tumour assessment; DCR was the proportion of patients treated in the lead-in stage
with an overall response of CR, PR and SD at the week 12 tumour assessment.
a For patients who achieved the best response of a confirmed CR/PR, the first response date and confirmation date may occur at different study
stages. Only first CR/PR occurrence is being summarised.
b For each cohort, one patient was excluded from the analysis during the lead-in stage due to lack of measurable disease at baseline.
c DCR determined at week 12.
d Median DOR was not determined for this cohort because of the low number of responses observed.















































Fig. 2. Best change of the sum of target lesions from baseline in all evaluable patients (A) and in evaluable patients who achieved ‡30%
reduction (B). Note: 3 of 459 patients who were evaluable for objective response at week 12 were not evaluable for this analysis. CRPC,
castration-resistant prostate cancer; GC, gastric/gastroesophageal junction adenocarcinoma; HCC, hepatocellular carcinoma; MBC,
metastatic breast cancer; MEL, melanoma; NSCLC, nonesmall cell lung cancer; OC, ovarian cancer; PAC, pancreatic adenocarcinoma;
SCLC, small-cell lung cancer.
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The goal of this RDT was to use the multi-tumour
design as a screening tool to identify up to two tumour-
specific cohorts that could be expanded to provide a
sufficient number of patients with SD during the lead-in
stage for generation of clinically meaningful PFS results
during the randomised stage.
The study accrued within the estimated timelines.
During the lead-in stage, cabozantinib demonstrated
preliminary clinical activity in multiple tumour types.
ORR 10% was observed in three tumour cohorts (OC,
MBC and NSCLC), and DCR at week 12  40%
occurred in six tumour cohorts (HCC, CRPC, OC,
MBC, NSCLC and MEL). Responses in patients treated
with cabozantinib appeared to be durable and rangedfrom 3.3 months in MBC to 11.2 months in OC. In the
three tumour cohorts with the highest numbers of
patients in the randomised stage (CRPC, MEL and
HCC), improved median PFS for cabozantinib treat-
ment compared with placebo was observed. The analysis
of overall PFS from the start of the study in the CRPC
and HCC cohorts supported the PFS results obtained in
the randomised stage.
The RDT design required periodic review of efficacy
and safety across all tumour cohorts to adequately
maintain enrolment within the scope of the study. Re-
view of interim efficacy results led to the closure of the
GC, SCLC and PAC cohorts after approximately 20
enrolled patients because these participants were deemed
unlikely to benefit from cabozantinib. The other cohorts
were allowed to continue with enrolment beyond 20
Table 2
Adverse events in 10% of patients (any grade) or 5% of patients
(grade III) irrespective of whether the event was considered by the
investigator to be related to cabozantinib treatment (N Z 526).
Preferred term All, n (%) Grade III, n (%)
Patients with at least one event 524 (99.6) 392 (74.5)
Fatigue 345 (65.6) 65 (12.4)
Diarrhoea 317 (60.3) 55 (10.5)
Nausea 273 (51.9) 16 (3.0)
Decreased appetite 271 (51.5) 26 (4.9)




179 (34.0) 46 (8.7)
Constipation 171 (32.5) 11 (2.1)
Weight decreased 165 (31.4) 11 (2.1)
Dysgeusia 156 (29.7) 0
Dysphonia 142 (27.0) 0
Hypertension 127 (24.1) 55 (10.5)
Abdominal pain 126 (24.0) 29 (5.5)
Asthenia 118 (22.4) 32 (6.1)
Dyspnoea 109 (20.7) 21 (4.0)
Rash 102 (19.4) 5 (1.0)
Stomatitis 99 (18.8) 4 (0.8)
Aspartate aminotransferase increased 94 (17.9) 16 (3.0)
Pain in extremity 90 (17.1) 11 (2.1)
Cough 88 (16.7) 2 (0.4)
Dry mouth 87 (16.5) 0
Dizziness 87 (16.5) 4 (0.8)
Mucosal inflammation 84 (16.0) 4 (0.8)
Dehydration 84 (16.0) 29 (5.5)
Headache 80 (15.2) 4 (0.8)
Back pain 79 (15.0) 15 (2.9)
Oedema peripheral 78 (14.8) 4 (0.8)
Alanine aminotransferase increased 71 (13.5) 10 (1.9)
Hypomagnesaemia 70 (13.3) 2 (0.4)
Oral pain 68 (12.9) 2 (0.4)
Anaemia 66 (12.5) 21 (4.0)
Hypothyroidism 66 (12.5) 2 (0.4)
Dyspepsia 64 (12.2) 2 (0.4)
Hypokalemia 64 (12.2) 15 (2.9)
Urinary tract infection 64 (12.2) 7 (1.3)
Oropharyngeal pain 60 (11.4) 1 (0.2)
Thrombocytopaenia 58 (11.0) 11 (2.1)
Muscle spasms 56 (10.6) 0
Dry skin 54 (10.3) 0
Pulmonary embolism 29 (5.5) 29 (5.5)
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CRPC cohort (NZ 171). Suspension of the randomised
stage was based on better than anticipated efficacy results
(e.g. ORR in the OC cohort and high DCRs) as well as
reports of symptomatic improvements (e.g. clinically
relevant pain palliation in patients with CRPC with bone
metastases), bone scan resolution and rapid clinical
deterioration among patients randomised to placebo
after achieving SD with cabozantinib during the lead-in
stage (Supplementary Fig. S1). For these reasons, the
RDT was converted to an open-label, non-randomised
study with two expansion cohorts in CRPC and OC.
Detailed results for the CRPC, MBC, MEL, HCC and
OC cohorts as well as the CRPC non-randomised
expansion cohort are reported separately [10e15].The termination of the randomised stage of the study
before achieving the maximum-allowed cohort enrol-
ment limited the ability to draw definitive conclusions
about PFS results. Nonetheless, the totality of the effi-
cacy results throughout the study warranted further
evaluation of cabozantinib activity in selected tumour
types, including phase III studies in CRPC (ClinialTrials.
gov, NCT01605227 [16] and NCT01522443) and an
ongoing phase III study in HCC (NCT01908426).
The safety results with cabozantinib were consistent
with those for patients with advanced cancer treated
with VEGFR TKIs [17]. The observed AEs were similar
to findings in other cabozantinib trials, and AEs were
generally manageable with dose modifications and
optimised supportive care.
In addition to the tumour types evaluated in this
study, cabozantinib has been evaluated and granted
regulatory approval for other oncology indications.
Based on results from randomised phase III trials,
cabozantinib tablets (60 mg) are approved for patients
with advanced renal-cell carcinoma who have received
prior anti-angiogenic therapy [18,19], and cabozantinib
capsules (140 mg) are approved for patients with pro-
gressive, metastatic medullary thyroid cancer [20].
In summary, this phase II multi-cohort RDT allowed
simultaneous evaluation of clinical activity and safety
for cabozantinib in several tumour types. CRPC and
OC were identified for further evaluation in open-label,
non-randomised expansion cohorts, and the data
collected for the CRPC and HCC cohorts supported the
initiation of phase III programs in these indications.Conflict of interest statement
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